PharmaLundensis AB Logo

PharmaLundensis AB

PHAL | SPGR

Overview

Corporate Details

ISIN(s):
SE0003359710 (+5 more)
LEI:
54930082I88D5N3GQ506
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

PharmaLundensis AB is a pharmaceutical research and development company focused on creating treatments that bind and excrete heavy metals like mercury, lead, and cadmium from the body. The company's primary drug candidate, PHAL-501, is a non-absorbable substance designed to operate within the intestine to capture and remove these toxins. This novel therapeutic approach is being developed to treat several diseases potentially caused or exacerbated by heavy metal toxicity, with key target indications including Chronic Obstructive Pulmonary Disease (COPD), chronic bronchitis, and depression. The mechanism is intended to provide significant health improvements with a high safety profile, as the drug does not enter the bloodstream.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for PharmaLundensis AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PharmaLundensis AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PharmaLundensis AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Tord Staffan Håkan Skogvall Other Buy 2,337 1,986.45 SEK
2025-01-17 SkåneÖrnen AB Other Buy 121,700 96,143.00 SEK
2025-01-17 Tord Staffan Håkan Skogvall Other Buy 10,958 7,999.34 SEK
2024-10-14 SkåneÖrnen AB Other Buy 49,370 19,748.00 SEK
2024-10-09 Tord Staffan Håkan Skogvall Other Buy 27,936 10,336.32 SEK
2024-09-26 SkåneÖrnen AB Other Buy 63,000 29,610.00 SEK
2024-09-20 Bo Wennergren Other Buy 60,000 27,600.00 SEK

Peer Companies

Company Country Ticker View
VERICI DX PLC Logo
AI-powered diagnostic tests for the kidney transplant market, predicting organ rejection and injury.
United Kingdom VRCI
Vicore Pharma Holding Logo
Develops AT2 receptor drugs and a digital therapeutic for pulmonary fibrosis.
Sweden VICO
Vivoryon Therapeutics N.V. Logo
Develops small molecule therapies for severe age-related, inflammatory, and neurodegenerative diseases.
Germany VVY
R&D in renewable energy & manufacturing specialized tools for automotive & engineering.
Slovakia N/A
Xintela AB Logo
Develops stem cell therapies and targeted antibody treatments for cancer and osteoarthritis.
Sweden XINT
Xlife Sciences AG Logo
A life sciences incubator commercializing early-stage academic research for healthcare markets.
Switzerland XLS
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage therapeutics for autoimmune diseases.
Israel XTLB
Yoshi Innovation Spolka Akcyjna Logo
A tech fund incubating MedTech, biotech, and defense ventures with investment and IP protection.
Poland YOS
Zealand Pharma Logo
Develops innovative peptide medicines for metabolic and rare diseases.
Denmark ZEAL
Ziccum AB Logo
Licenses drying tech for thermostable vaccines & biologics, eliminating the cold chain.
Sweden ZICC